European Lead Factory one of IMI’s most high-profile projects
Until now, the Innovative Medicines Initiative (IMI) has launched almost 100 projects to tackle the barriers that currently limit the efficiency, effectiveness and quality of medical research and drug development.
With six running target programmes, the virtual biotech The Research Network is unsurpassed in submitting interesting drug discovery programmes for screening by the European Lead Factory (ELF).
Joint European Compound Library >500 000 compounds
The European Lead Factory set out to assemble a screening collection of half a million compounds. Now, that ambitious goal has been reached. A truly pan-consortium achievement.
During the lifetime of the European Lead Factory (ELF), both the number of screens performed per year and the size of the Joint European Compound Library have increased steadily.
Spin-out Keapstone Therapeutics receives further funding
Based on the hits generated by the European Lead Factory, Dr Richard Mead, University of Sheffield, started the spin-out virtual biotech Keapstone Therapeutics, a world-first type of partnership between Parkinson's UK and the University of Sheffield. Keapstone Therapeutics aims to develop a new therapy for motor neurone disease (MND/ALS) and/or Parkinson’s disease.
ELF Chemistry event brings together scientists in Belgium
The European Lead Factory (ELF) acknowledges the need for open exchange between researchers with different professional backgrounds and puts a focus on the career development of young scientists. Therefore, the European Lead Factory annually invites young talented EU Lead Factory chemists from participating small and medium-sized enterprises (SMEs) and academic institutions to a so-called Learnings and Achievements meeting, where they can present their scientific work, interact with colleagues and liaise with representatives from participating established pharmaceutical companies and SME partners.
It is antimicrobial resistance (AMR) awareness week. AMR is a major threat for public health. Worldwide, researchers are looking for drugs that can slow down or even reverse resistance emergence.
The European Lead Factory congratulates 19 early career researchers that have been nominated to participate in the ELF Annual Chemistry Learning & Achievements meeting at the Janssen Campus (Janssen Pharmaceutica NV) in Beerse, Belgium, 6-7 November 2017!
The European infrastructure EU-OPENSCREEN and the European Lead Factory executives of the European Screening Centre and the Public Chemistry Consortium have signed a Memorandum of Understanding for collaboration in future initiatives.
Anyone, any disease, any target. About 20 years ago, Prof Frank Gunn-Moore, University of St Andrews discovered a protein, which he suspected was involved in the deterioration of the brain that causes dementia.